ClinicalTrials.Veeva

Menu

Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment

AstraZeneca logo

AstraZeneca

Status and phase

Completed
Phase 2

Conditions

Colorectal Neoplasms

Treatments

Drug: CP-675,206

Study type

Interventional

Funder types

Industry

Identifiers

NCT00313794
A3671014

Details and patient eligibility

About

This study is for patients with metastatic adenocarcinoma arising from the colon or rectum who have received treatment(s) for metastatic disease with subsequent disease progression. Patients who are intolerant to treatment(s) are also included. This is a study for good performance status colorectal cancer patients who have exhausted standard therapy options.

Enrollment

49 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Radiographic evidence of metastatic, progressive disease following standard therapies.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

Exclusion criteria

  • Known brain metastases or uncontrolled pleural effusions.
  • History of chronic inflammatory or autoimmune disease.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

49 participants in 1 patient group

1
Experimental group
Description:
single arm
Treatment:
Drug: CP-675,206

Trial contacts and locations

11

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems